Research and Markets: Chinese Market for Active Ingredients in Healthcare - potential growth of the API market is huge

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b7fb2a/chinese_market_for) has announced the addition of Frost & Sullivan's new report "Chinese Market for Active Ingredients in Healthcare" to their impressive offering of pharmaceutical research publications.

“Chinese Market for Active Ingredients in Healthcare”

Rapid growth of the pharmaceuticals industry is to propel the $5.52 Billion Chinese active pharmaceutical ingredients (API) Market towards $17.55 billion in 2017. This Frost & Sullivan research report provides information on two product types based on the two synthesis routes of synthetic and biotech active pharmaceutical ingredients (API). The authors thoroughly examine the following customer bases: innovative (branded) API and generic AP.

Apart from the sustained and rapid growth of the pharmaceuticals industry, the long-term use of multiple specialised drugs for an ageing population and the reform of the Chinese medical system have given a shot in the arm to the Chinese API market. Consequent to the reforms in the healthcare industry, the growing popularity of the medical insurance system is expected to drive the pharmaceuticals industry and thereby, the demand of API in China, says the analyst of this research. The Chinese Government plans to promote the drug master file (DMF) management method and develop a multi-level insurance system.

While the potential for the growth of the API market is huge, overcapacity for bulk products is greatly reducing the profitability of the manufacturers and suppliers. For instance, the proposed capacity of vitamin C, a representative of bulk products, is expected to be more than 200kt, which will be far more than the global demand of this product. Ingredient suppliers can offset the issue of expanding production capacities by adjusting their product portfolios in line with consumer trends. They can also achieve higher profits by focusing on the biotech API segment, which holds considerable potential, but currently accounts for a negligible share of the market. In addition, market participants can benefit from the expiration of patents by 2012, when nearly $80 billion worth of patented drugs including anti-tumour, cardiovascular and digestive will go off patent, notes the analyst. This will lead to robust growth opportunities and the generic API sector is well positioned to seize them.

Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

• Synthetic active pharmaceutical ingredients
• Biotech active pharmaceutical ingredients

Key Topics Covered:

• Chinese Active Ingredients Market in Healthcare
• Analysis on Customer Base
• Synthetic Active Ingredients Market in Healthcare
• Biotech Active Ingredients Market in Healthcare
• Market Strategies and Conclusions
• Company Profiles
• Decision Support Database

For more information visit http://www.researchandmarkets.com/research/b7fb2a/chinese_market_for